MDM2 and hematologic disorder: However, these p53-activating agents often exhibit dose-limiting adverse effects, which are most-commonly related to gastrointestinal and hematological disorders, and could be caused, at least in part, by elevated MDM2 expression subsequent to p53 activation induced by the small molecules.